• Extend survivability of primary cardiomyocytes, which is currently only a couple of weeks.
  • Identify methods by which stem cell-derived cardiomyocytes can be effectively freeze-thawed without loss of cell integrity (currently, there is about 25% cell loss during the hiPSC-CM freeze/thaw processes)
  • Identify the best serum-free, chemically defined freezing/thawing media (leading to highest cell survival) that can also be used for GMP-level production.
  • Identify growth factors and other components that may be able to protect cells and tissues during the freeze/thaw process or help with cell adhesion during the thaw process.
  • Integrate the knowledge base and experience of transplant researchers, particularly with regard to organ viability and preservation.  From an organ transplant perspective, preservation is an important issue with evolving technology from preservation fluid to hypo/normothermic perfusion. This technology can be adopted in the tissue engineering space, once a vascularized/perfuseable construct is made. 
  • Development of bioreactors to maintain cell/tissue viability in culture.

Join The Conversation